Biosyntech Inc. Receives Approval For Canadian BST-DermOn’R’ Pivotal Clinical Trial

LAVAL, QUEBEC--(CCNMatthews - Aug. 24, 2006) - BioSyntech Inc. (TSX VENTURE:BSY) announced today that it has received approval from Health Canada, Therapeutic Products Directorate, Medical Devices Bureau, to begin enrolling subjects in its pivotal clinical trial for BST-DermOn®, a medical device designed to repair chronic wounds. Entitled “A multicenter, prospective, randomized comparison study of BST-DermOn versus standard of care in the treatment of diabetic foot ulcers,” this trial is expected to provide data needed to support Canadian and European regulatory approvals of BST-DermOn®.